2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W970291
    N-Acetyl-S-(2-hydroxypropyl)-l-cysteine 923-43-3
    N-Acetyl-S-(2-hydroxypropyl) -l-cysteine is a metabolite of propylene oxide and is used as the biomarker of propylene oxide exposure. It is significantly positively associated with diabetes and dyslexia.
    N-Acetyl-S-(2-hydroxypropyl)-l-cysteine
  • HY-W970428
    15-Methylheptadecanoic acid 29709-08-8 98%
    15-Methylheptadecanoic acid is an ester product.
    15-Methylheptadecanoic acid
  • HY-W982688
    Palmitoleyl methane sulfonate 93135-85-4 98%
    Palmitoleyl methane sulfonate is an ester product.
    Palmitoleyl methane sulfonate
  • HY-W982689
    Fluindarol 6723-40-6 98%
    Fluindarol is a phenylindandione derivative and an orally active anticoagulant. Fluindarol acts as a toxicant that induces organ and tissue haemorrhages and liver parenchymal necrosis in rats. Fluindarol exhibits acute and cumulative preclinical toxicity in rats, rabbits, and dogs, with higher toxicity in female rats than male rats. Fluindarol lacks analgesic action, produces only minor blood pressure effects, and does not alter circulation, respiration, CNS, or cardiac activity. Fluindarol is considered too toxic for clinical use based on preclinical data.
    Fluindarol
  • HY-W986917
    Decyl methanesulfonate 41233-29-8 98%
    Decyl methanesulfonate is an ester product.
    Decyl methanesulfonate
  • HY-W988083
    Decarestrictin B 127393-91-3 98%
    Decarestrictin B is a decanolactone that can be isolated from penicillium strains. Decarestrictin B is an inhibitor of cholesterol biosynthesis.
    Decarestrictin B
  • HY-W988906
    6(Z),9(Z)-Octadecadienoic acid 28290-77-9 98%
    6(Z),9(Z)-Octadecadienoic acid is a fatty acid.
    6(Z),9(Z)-Octadecadienoic acid
  • HY-W992384
    (S,9E,11Z,14Z)-8-Hydroxyicosa-9,11,14-trienoic acid 889573-69-7 98%
    (S,9E,11Z,14Z)-8-Hydroxyicosa-9,11,14-trienoic acid is an ester product.
    (S,9E,11Z,14Z)-8-Hydroxyicosa-9,11,14-trienoic acid
  • HY-W992515
    9,10,16-Trihydroxyhexadecanoic acid 6949-98-0 98%
    9,10,16-Trihydroxyhexadecanoic acid is an ester product.
    9,10,16-Trihydroxyhexadecanoic acid
  • HY-W997026
    Glucokinase activator 7 66780-67-4 98%
    Glucokinase activator 7 is a Glucokinase activator. Glucokinase activator 7 can be used for research of diabetes, hyperglycemia and other diseases (Compound in Page 176 of Ref.).
    Glucokinase activator 7
  • HY-Y0078S1
    Cinnamyl Alcohol-d9 3028869-57-7 98%
    Cinnamyl Alcohol-d9 is deuterated labeled Cinnamyl Alcohole (HY-Y0045). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased PPARγ expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities.
    Cinnamyl Alcohol-d9
  • HY-Y0740S2
    4-Methoxybenzaldehyde-d2 95307-67-8 98%
    4-Methoxybenzaldehyde-d2 is the deuterium labeled 4-Methoxybenzaldehyde (HY-W041300). 4-Methoxybenzaldehyde (p-anisaldehyde) is a fragrant phenolic compound. 4-Methoxybenzaldehyde has been found in many plant species including horseradish, anise, star anise. 4-Methoxybenzaldehyde is a possible neurotoxicant and it has shown effects that include mortality, attractancy, and interference with host seeking .
    4-Methoxybenzaldehyde-d2
  • HY-Y1031AR
    3-Ethoxy-3-oxopropanoic acid potassium (Standard) 6148-64-7 98%
    3-Ethoxy-3-oxopropanoic acid (potassium) (Standard) is the analytical standard of 3-Ethoxy-3-oxopropanoic acid (potassium) (HY-Y1031A). This product is intended for research and analytical applications. 3-Ethoxy-3-oxopropanoic acid potassium is an endogenous metabolite. 3-Ethoxy-3-oxopropanoic acid potassium promotes plant growth.
    3-Ethoxy-3-oxopropanoic acid potassium (Standard)
  • HY-100116AR
    Mitoquinone mesylate (Standard) 845959-50-4
    Mitoquinone (mesylate) (Standard) is the analytical standard of Mitoquinone (mesylate) (HY-100116A). This product is intended for research and analytical applications. Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.
    Mitoquinone mesylate (Standard)
  • HY-100303AR
    FR194738 (Standard) 204067-52-7 98%
    FR194738 (Standard) is the analytical standard of FR194738 (HY-100303A). This product is intended for research and analytical applications. FR194738 is a squalene epoxidase inhibitor. FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.
    FR194738 (Standard)
  • HY-100304AR
    KW-8232 (Standard) 217813-15-5 98%
    KW-8232 (Standard) is the analytical standard of KW-8232 (HY-100304A). This product is intended for research and analytical applications. KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232 (Standard)
  • HY-100313AR
    YM-53601 (Standard) 182959-33-7 98%
    YM-53601 (Standard) is the analytical standard of YM-53601 (HY-100313A). This product is intended for research and analytical applications. YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation.
    YM-53601 (Standard)
  • HY-100530CR
    Sp-cAMPS sodium salt (Standard) 142439-95-0 98%
    Sp-cAMPS (sodium salt) (Standard) is the analytical standard of Sp-cAMPS (sodium salt) (HY-100530C). This product is intended for research and analytical applications. Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS sodium salt (Standard)
  • HY-100619AR
    BMS-986020 sodium (Standard) 1380650-53-2 98%
    BMS-986020 (sodium) (Standard) is the analytical standard of BMS-986020 (sodium) (HY-100619A). This product is intended for research and analytical applications. BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).
    BMS-986020 sodium (Standard)
  • HY-100672BR
    (2R)-SR59230A (Standard) 1932675-95-0 98%
    (2R)-SR59230A (Standard) is the analytical standard of (2R)-SR59230A (HY-100672B). This product is intended for research and analytical applications. (2R)-SR59230A is the isomer of SR59230A (HY-100672), and can be used as an experimental control. SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
    (2R)-SR59230A (Standard)
Cat. No. Product Name / Synonyms Application Reactivity